Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA approves Lundbeck's Onfi for rare, severe epileptic seizures

This article was originally published in Scrip

Executive Summary

Lundbeck and its US manufacturing partner Catalent Pharma won US FDA approval of Onfi (clobazam) as an adjunctive treatment for seizures in patients two years and up with Lennox-Gastaut syndrome, a rare but severe form of epilepsy.

You may also be interested in...



Dravet Syndrome: A Rare Epilepsy, Now With Two Approved Treatments

Biocodex's Diacomit – long approved in the EU – just won FDA approval. That brings the number of drugs cleared for Dravet in the US to two, including GW Pharma's recently endorsed Epidiolex, and the R&D pipeline for this rare seizure disorder is growing.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Allergan's Price Reform Pledge: Will Others Follow?

Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.

Topics

Related Companies

UsernamePublicRestriction

Register

SC014968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel